Navigation Links
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Date:9/5/2007

Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, but many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for the treatment of platinum-resistant or -refractory SCLC in nearly a decade.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional infor
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and HOUSTON, TX , Feb. 27, ... (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom ... contractual lock-up (the "Lock-Up") 2,353,130 common shares of the ... originally subject to the Lock-Up. Of the Common Shares ... trading immediately upon release from the Lock-Up while the ...
(Date:2/27/2015)... 27, 2015  Boston Scientific Corporation (NYSE: ... 2015 Annual Healthcare Conference on March 10 in ... Brennan , executive vice president and chief financial officer, ... will participate in a 25-minute question and answer session ... 1:05 p.m. ET. Following a 5-minute break, a question ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015   Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Disorders™ (NORD™), the European Organisation for Rare Diseases™ ... the world in observing Rare Disease Day. ... year, patient organizations, industry, and other participants conduct ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... ATLANTA, April 19, 2011 Alison MacNeil issued the ... is running on PBS this week: ... not know vaccine manufacturers are not required to test ... remains largely unknown. Many thousands of parents with Autistic ...
... April 18, 2011 CryoLife, Inc. (NYSE: ... tissue processing company, announced today that 2011 first quarter ... 2011.  On that day, the Company will hold a ... Time to discuss the results, followed by a question ...
Cached Medicine Technology:Daughter of Journalist Robert MacNeil States that Son Regressed Into Autism After Vaccines 2CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results 2
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External Counterpulsation ... The Heart Fit Clinic is also selling the machines ... The goal is to scale the business to help ... buy External Counterpulsation machines can be difficult process. ... process and achieve the desired results. , The ...
(Date:2/28/2015)... February 28, 2015 Mew and Company, ... that they now provide business consulting services in addition ... corporate tax planning and succession planning. Company finances are ... experienced professionals. On top of this, complex Canadian tax ... corporate accounting. As a result, Mew and Company works ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 Pioneer ... the 2015 Japan Architecture & Construction Materials Show, an ... join more than 1,000 suppliers and top manufacturers of ... Reclaimed wood products sourced and manufactured by ... have found popularity in Japan at restaurants, hotels, retailers, ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... developed for preventing and treating the flue have shown ... dose to be effective.// The compounds, known collectively as ... relenza, or zanamivir, which the U.S. Food and Drug ... B. ,Researchers reported at the International Conference on ...
... to be worrisome threats, common pest control agent called ... treatments in eradicating deadly bacterial spores from buildings. Tests ... 50 years to control insect pests in buildings, grain ... than current treatments such as chlorine dioxide for killing ...
... giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug, ... - in the wake of unproven reports in the UK, ... , ,Touted to be the world’s most successful smoking cessation ... June 2001. The cause for concern, however, was a safety ...
... University Hospital, a common cholesterol fighting drug, a statin ... heart complications by up to 20 percent for about ... heart events -- such as dying of heart disease ... Dr. Patrick Serruys,// professor of interventional cardiology at Erasmus ...
... the Marquette University School of Dentistry suggest chronic periodontal ... diabetes.//The research ties the incidence of diabetes in patients ... the bloodstream that triggers a reaction from the immune ... release proteins called cytokines that can disrupt production of ...
... University of Texas in US have found that African American ... women.// Ovarian cancer causes more deaths than any other cancer ... ethnicity is an independent risk factor in prognosis. US researchers ... 600 African American women with ovarian cancer. They find that ...
Cached Medicine News:Health News:Cholesterol Drug Helps After Angioplasty 2Health News:Cholesterol Drug Helps After Angioplasty 3
... heart surgery is no longer the only ... in young children and in patients with ... are seeking non-surgical options to close inter-atrial ... a permanently implanted prosthesis and catheter delivery ...
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... Testing and Quality Assurance (for Waived and ... POLs, clinics and small hospitals maintain laboratory ... of patient lab results and assist labs ... opportunity to earn 12 P.A.C.E. Contact hours ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
Medicine Products: